Efficacy of leflunomide combined with ligustrazine in the treatment of rheumatoid arthritis: prediction with network pharmacology and validation in a clinical trial

BACKGROUND: Leflunomide (LEF) is a first-line disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis (RA). However, there are still a few nonresponders. It is logical to suggest that employing combinations including LEF that produce synergistic effects in terms of pharmacological acti...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Chi, Guan, Daogang, Jiang, Miao, Liang, Chao, Li, Li, Zhao, Ning, Zha, Qinglin, Zhang, Wandong, Lu, Cheng, Zhang, Ge, Liu, Jian, Lu, Aiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679497/
https://www.ncbi.nlm.nih.gov/pubmed/31388350
http://dx.doi.org/10.1186/s13020-019-0247-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679497/
https://www.ncbi.nlm.nih.gov/pubmed/31388350
http://dx.doi.org/10.1186/s13020-019-0247-8

Ejemplares similares